[Preprint] Estudo randomizado | Ivermectina não beneficia pacientes com COVID-19 leve a moderada no ambiente ambulatorial.

Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial – medRxiv

Comentário: Study finds no benefit to taking ivermectin for COVID-19 symptoms – Duke University